Investigative & Mechanistic Toxicology
We are experts in the design, performance and interpretation of preclinical investigative and mechanistic toxicology programs. These programs are typically intended to explain the toxicological mode of action / adverse outcome pathway (AOP) affected by the compound under investigation. Using this knowledge, we explain previously observed preclinical toxicities and evaluate the actual hazard and/or risk to humans.
Our experience spans the agrochemical, chemical, pharmaceutical and consumer products industries. Mechanistic data generated at CXR are frequently used in regulatory submissions.
CXR Biosciences will work with you to design comprehensive investigative safety studies. We typically use a hypothesis driven approach, for instance as outlined in the diagram below.
- Identify the basis for chemical induced toxicity observed in animal studies
- A putative mechanism proposed for the mode of action (MOA)
- A series of studies designed to test the hypothesis
- Develop an in vitro system to model the in vivo toxicity MOA
- Assess potential hazard to humans by evaluating MOA in human in vitro system
Areas of expertise at CXR include:
- Designing and running preclinical programs to identify the underlying toxicological mode of action / AOP in a broad range of organs and cell types.
- determining the relevance of rodent non genotoxic carcinogenicity to man.
- Testicular toxicity
- endocrine toxicity
- primary cell culture and toxicogenomics / pathways analysis
- mechanistic nanotoxicology and respiratory toxicology
- REACH read-across (short-term mechanistic studies to support read-across conclusions in support of REACH registrations
For further information about our services, or to discuss a specific issue, please contact us.
Download the Investigative & Mechanistic Toxicology brochure here